Posterior polymorphous corneal dystrophy 1 (PPCD1) is a genetic disorder that affects corneal endothelial cell function and leads to loss of visual acuity. PPCD1 has been linked to a locus on chromosome 20 in multiple families; however, Sanger sequencing of protein-coding genes in the consensus region failed to identify any causative missense mutations. In this study, custom capture probes were utilized for targeted next-generation sequencing of the linked region in a previously reported family with PPCD1. Variants were detected through two bioinformatics pipelines and filtered according to multiple criteria. Additionally, a high-resolution microarray was used to detect copy number variations. No non-synonymous variants in the protein-coding region of annotated genes were identified. However, 12 single nucleotide variants in 10 genes, and 9 indels in 7 genes met the filtering criteria and were considered candidate variants for PPCD1. Eleven single nucleotide variants were confirmed by Sanger sequencing, including 2 synonymous variants and 9 non-coding variants, in 9 genes. One microdeletion was detected in an intron of OVOL2 by microarray but was subsequently not identified by PCR. Using a comprehensive next-generation sequencing approach, a total of 16 genes containing single nucleotide variants or indels that segregated with the affected phenotype in an affected family previously mapped to the PPCD1 locus were identified. Screening of these candidate genes in other families previously mapped to the PPCD1 locus will likely result in the identification of the genetic basis of PPCD1.
Introduction
The corneal dystrophies are a heterogeneous group of genetic disorders that are associated with bilateral, progressive loss of visual acuity due to changes in the cornea [1] . Four corneal dystrophies, posterior polymorphous corneal dystrophy (PPCD), Fuchs endothelial corneal dystrophy, congenital hereditary endothelial dystrophy, and X-linked endothelial corneal dystrophy, affect the corneal endothelium and are collectively known as the endothelial corneal dystrophies.
Reykjavik, Iceland) was used to enrich for the previously linked chromosome 20 region in this family and an additional 500 Kbp 5' of the linked interval (hg19: 17.3 Mbp-31.8 Mbp). Highly repetitive regions such as the centromere were excluded from enrichment. High-throughput sequencing was performed on the Illumina HiSeq2000 platform (Illumina, Inc., San Diego, CA).
Variant calling bioinformatics pipelines
FASTQ files were downloaded from the UCLA Clinical Microarray Core and processed with two independent bioinformatics pipelines.
Burrows Wheeler Aligner/GATK HaplotypeCaller pipeline (BWA/GATK). All reference files for this pipeline were obtained from the Broad Institute's reference file directory (https://www.broadinstitute.org/gatk/download/) associated with UCSC's hg19 human reference genome. Files were then processed and analyzed according to recommendations from the Genome Analysis Toolkit (GATK) Best Practices Pipeline [15] [16] [17] . FASTQ files were first aligned to the hg19 reference genome with the Burrows Wheeler Aligner (BWA, http://biobwa.sourceforge.net/) for paired-end reads [18] . After alignment, Picard Tools was used to convert files from SAM to BAM, sort by genomic coordinates, and mark optical duplicates (http://broadinstitute.github.io/picard/). Files were then realigned to known indels using GATK. Variant calling for single-nucleotide variants (SNVs) and insertions/deletion (indels) was then conducted with GATK's HaplotypeCaller algorithm.
BowTie2/SAMtools pipeline (BT2/SAM). Using Partek1 Flow1 (Partek Inc., St. Louis, MI), FASTQ files were aligned to the hg19 human reference genome with BowTie2, and variant calling for SNVs and indels were performed with SAMtools using default settings.
Variant filtering and annotation
Variant output files from both bioinformatics pipelines were analyzed using Partek1 Genomics Suite1 platform. The following criteria were utilized to filter candidate variants: (1) within the enriched interval (chr20: 17,316,434 bp-26,319,280 bp and 29,420,138 bp-31,826,081 bp); (2) read depth of 5; (3) quality score 20; (4) heterozygous, (allele frequency from 0.4-0.7); (5) not present in unrelated, unaffected controls; (6) present in affected family members and absent in unaffected family members; and (7) rare or novel (minor allele frequency (MAF) 0.05). MAFs were assigned using the Database of Single Nucleotide Polymorphisms (National Center for Biotechnology Information, National Library of Medicine; Bethesda, MD [dbSNP Build ID: 138]), and novel variants were defined as lacking a reference SNP cluster ID. After filtering, SNVs were then annotated with the Ensembl (v75) and RefSeq (compiled 02-02-2015 by Partek Inc.) annotation databases. SNVs were categorized as missense, nonsense, synonymous, 5' or 3' splice site, 5' or 3' untranslated region (UTR), promoter, intronic, or non-coding RNA (ncRNA). Indels were annotated with only the Ensembl (v75) database using Ensembl's Variant Effect Predictor tool (VEP, http://grch37.ensembl.org/info/ docs/tools/vep/index.html).
SNV validation and screening of additional family members
Sanger sequencing was performed to validate the filtered NGS-detected SNVs. Validated SNVs located in protein-coding genes were screened for in an additional 19 family members (seven affected and 12 unaffected). Novel SNVs in protein-coding genes were screened for in 100 ethnically matched controls. Sequencing primers are given in S1 Table. In silico analysis of filtered promoter region SNVs and synonymous substitutions identified in protein-coding genes Variants identified within the promoter regions of protein-coding genes were analyzed using JASPAR (http://jaspar.genereg.net/) in order to detect possible changes within transcription factor binding sites [19] . A threshold cutoff score of 75% was used. In addition, cryptic splice site prediction for synonymous SNVs was performed using MutPred Splice (http://mutdb.org/ mutpredsplice/submit.htm) and NetGene2 (http://www.cbs.dtu.dk/services/NetGene2) [20, 21] .
Determination of corneal endothelial expression of protein-coding genes in which validated, filtered, SNVs were identified Transcript levels of OVOL2, CCM2L and THBD in the corneal endothelium were previously determined by RNA-seq, while the level of the encoded proteins was determined by fluorescence-immunohistochemistry (F-IHC) [22] . A cadaveric donor cornea from an unaffected individual and two corneas from individuals with PPCD without a ZEB1 mutation (non-PPCD3) obtained at time of surgery were fixed in 10% Tris-buffered formalin and subsequently paraffin embedded. Immunodetection was performed using a standard immunohistochemistry protocol with antibodies directed against OVOL2, CCM2L and THBD (S2 Table) . In brief, sections were deparaffinized in Histo-Clear (National Diagnostics, Atlanta, GA) and rehydrated through a series of alcohols (100%, 95% and 80%) and water. Antigen retrieval was performed using proteinase-K digestion at 37°C for 15 minutes and sections were washed in PBST (PBS and 0.5% Tween 20) . Non-specific epitope blocking was achieved by a 1 hour incubation with PBST supplemented with 1% bovine serum albumin and 10% normal serum. The sections were subsequently incubated overnight with each primary antibody diluted 1:500 (OVOL2) or 1:100 (CCM2L and THBD) in blocking buffer, followed by three washes in PBST. Incubation with a secondary antibody, Alexa Fluor 594 (Life Technologies, Carlsbad, CA), diluted 1:500 in blocking buffer was performed. After washing three times with PBST and one time with PBS, sections were mounted with Vectashield aqueous mounting medium containing 4 0 ,6-diamidino-2-phenylindole (Vector Laboratories Inc., Burlingame, CA). To account for non-specific fluorescence, a control was performed using only the secondary antibody. Images were obtained using a fluorescence confocal microscope. Quantification of the fluorescence signal corresponding to each protein was performed using the Volocity 3D Image Analysis Software (PerkinElmer, Waltham, MA). Final fluorescence quantities were determined by subtracting non-specific fluorescence values, which were obtained by measuring the fluorescence in a field devoid of tissue in each image from the fluorescence in the endothelium of the secondary-only control.
Copy number variant analysis using high-resolution array comparative genomic hybridization
Copy number variation (CNV) analysis was performed using genomic DNA samples from the aforementioned four affected and four unaffected individuals that underwent NGS. The genomic DNA samples were submitted to the UCLA Clinical Microarray Core for array comparative genome hybridization (aCGH) using a custom Agilent 8x60K array (Agilent Technologies, Inc., Santa Clara, CA). Interrogation of a 16.7 Mbp region (hg19: 17.3 Mbp-34.0 Mbp) encompassing the linked PPCD1 locus and approximately 2.7 Mbps (0.54 Mbp 5' and 2.17 Mbp 3') of sequence flanking the PPCD1 locus was performed using 52,828 oligonucleotide probes. This design resulted in a median probe spacing of 159 bp. Data analysis was performed using the Agilent CytoGenomics 3.0 software. The raw data files are available from the GEO DataSets database (accession number GSE72617; National Center for Biotechnology Information [NCBI], Bethesda, MD, USA). CNV validation was performed using agarose gel electrophoresis of PCR products amplified with primers flanking the putative CNV (S1 Table) .
Results

Sequencing reads align to the enriched region
After performing alignment algorithms using two bioinformatics pipelines, NGS reads from one representative sample that underwent NGS were confirmed to align to the enriched region on chromosome 20 (Fig 2) . Oligonucleotide probes for regions of low complexity (e.g., centromere) were avoided and therefore lack reads.
Comparison of two bioinformatics pipelines for the detection of SNVs
After variant filtering, a comparison of SNVs detected by the BT2/SAM and BWA/GATK pipelines was conducted to determine concordance between the two bioinformatics pipelines. The BT2/SAM pipeline detected a total of 839 SNVs and the BWA/GATK pipeline detected a total of 885 SNVs. Of these, 820 SNVs were concordant between both pipelines, while 19 SNVs were detected by only BT2/SAM and 65 SNVs were detected by only BWA/GATK.
Comparison of two gene annotation databases for the classification of identified SNVs
After performing variant filtering, a comparison of annotated SNVs was conducted to determine concordance between annotation databases for each bioinformatics pipeline. For the BT2/SAM pipeline, 386 SNVs were annotated by the RefSeq database, 441 SNVs were annotated by the Ensembl database, and 384 annotated variants were concordant between both annotation databases ( Fig 3A) . For the BWA/GATK pipeline, 409 SNVs were annotated by the RefSeq database, 469 SNVs were annotated by the Ensembl database, and 407 SNVs were concordant between both annotation databases ( Fig 3B) .
SNV and indel variant analysis of the PPCD1 interval
SNV analysis. The majority of detected SNVs were intergenic SNVs (not annotated) or annotated as intronic or ncRNA SNVs (data not shown). A total of 12 SNVs located in 10 genes that were neither intronic nor ncRNA passed our filtering criteria ( Table 1 ). Three of the 10 genes were protein-coding: OVOL2, THBD and CCM2L. Two of the 12 SNVs were coding region variants, resulting in synonymous substitutions in OVOL2 and CCM2L. Nine of the 12 SNVs were located in the promoter regions of eight genes, including two variants in the promoter region of OVOL2. The remaining SNV was located in the 3' untranslated region (UTR) of THBD. Of the two SNVs that were novel, only one, NM_021220:c.-307T>C in OVOL2, affected a protein-coding transcript.
Indel analysis. Since indel realignment is not available in Partek1 Flow1, only indels detected by the BWA/GATK pipeline were analyzed to determine segregation with the affected phenotype. Due to difficulties in indel annotation in Partek1 Genomics Suite1, Ensembl's VEP tool was utilized to annotate indels. A total of 168 indels segregated with the affected status, with 159 indels annotated as intergenic or intronic. The remaining nine indels were located in seven genes, all of which were protein-coding ( Table 2) . Validation of these nine indels was not performed since the majority of the indels are located in regions of low complexity. Five of the nine indels were insertions located in intron 1 of CRNKL1 and the promoter of C20orf26 while the other four indels were located in the non-coding regions of five different genes. One of these four indels, which was mapped to the intronic region of HCK, was also mapped to the exonic region of a non-protein-coding transcript for HCK within the Ensembl database.
SNV validation and screening of additional family members
Of the 12 SNVs that survived the filtering criteria, 11 SNVs were confirmed by Sanger sequencing to be present in the four affected individuals who underwent NGS (the SNV in FAM182A (n.-452C>T) was not detected) and each was confirmed to be absent in the four unaffected individuals who underwent NGS (S1 Fig). Four of the 12 SNVs (OVOL2 c.327C>A; OVOL2 c.-307T>C; THBD c.351A>G; CCM2L c.1107G>A) were located in protein-coding genes. Nineteen additional family members (7 affected and 12 unaffected) who did not undergo NGS were screened for each of these four SNVs. Three of the four SNVs (OVOL2 c.327C>A, OVOL2 c.-307T>C, and THBD c.351A>G) segregated with the affected status of the additional family members. Although present in all affected family members, CCM2L c.1107G>A was also identified in one unaffected family member. OVOL2 c.-307T>C, the only novel SNV found within a protein-coding gene, was not found in 100 controls.
In silico analysis of promoter region SNVs and synonymous substitutions identified in protein-coding genes
Of the variants that passed the filtering criteria, OVOL2 c.-307T>C was the only variant found within the promoter region of a protein-coding gene. Thus, this variant was analyzed to determine whether it could cause any changes to the transcription factor binding sites within the OVOL2 promoter. According to JASPER, OVOL2 c.-307T>C is predicted to cause the formation of an additional FOXO3 enhancer transcription factor binding site (with a relative score of 77.8%) to the OVOL2 promoter. Of the other variants that passed the filtering criteria, OVOL2 c.327C>A and CCM2L c.1107G>A were annotated as synonymous substitutions. Thus these variants were analyzed with MutPred Splice and NetGene2 to determine whether a cryptic splice site would be created. MutPred Splice predicted that the synonymous substitution in exon 3 of OVOL2 (c.327C>A) was a splice neutral variant with a score of 0.17. Additionally, NetGene2 did not predict that this synonymous substitution in OVOL2 would alter splicing, predicting the wild type splice acceptor and splice donor sites that flank exon 3 with confidence values of 1.00. MutPred Splice predicted that the synonymous substitution in exon 7 of CCM2L (c.1107G>C) was also a splice neutral variant with a score of 0.09 while NetGene2 predicted the creation of a splice acceptor site with a confidence of 0.19. The wild type splice acceptor site flanking exon 7 of CCM2L was predicted with a confidence value of 0.33, and the wild type splice donor site was predicted with a confidence value of 0.95.
Expression of OVOL2, CCM2L and THBD in PPCD corneal endothelium
A recent study using RNA-seq to profile the ex vivo human corneal endothelial cell transcriptome demonstrated transcript levels for OVOL2 (0.03 RPKM) and CCM2L (0.00 RPKM) at levels significantly below the background cutoff of 1 RPKM, while THBD (50.87 RPKM) was significantly above this cutoff [22] . Expression of the proteins encoded by OVOL2, CCM2L and THBD was investigated using F-IHC (Fig 4) . In agreement with the transcript levels determined by RNA-seq, THBD was detected in the normal donor endothelium while OVOL2 and CCM2L were not. Similarly, one of the PPCD corneas did not show expression of OVOL2 or Copy number variant analysis of the PPCD1 interval CNV analysis was performed to identify a potentially pathogenic microdeletion or microinsertion in the PPCD1 interval. DNA samples from the four affected and the four unaffected individuals for whom NGS was performed were subjected to high-resolution aCGH. Fourteen CNVs (7 gains and 7 losses) were identified in at least one individual and ranged in size from 121 to 413,066 base pairs. A single CNV (318 bp loss) within an intron of OVOL2 was identified in all the affected individuals but none of the unaffected individuals. However, subsequent validation by PCR did not identify the 318 bp loss in the region predicted by aCGH (data not shown).
Discussion
In this study, we present, to the best of our knowledge, the first screening of the PPCD1 interval to identify potentially pathogenic coding and non-coding SNVs, indels and CNVs. NGS was used to sequence the entire linked region, which includes the PPCD1 common support interval, excluding regions of low complexity such as the centromere. With adequate coverage of the sequenced region, two independent bioinformatics pipelines were utilized for alignment and variant calling, and two independent annotation databases were utilized to annotate SNVs. Indels were analyzed and annotated using only the BWA/GATK pipeline and the Ensembl annotation database. After performing genetic filtering, a total of 11 validated candidate SNVs in nine genes and nine non-validated indels in seven genes were identified. Additionally, aCGH was used to interrogate CNVs in the linked region, although the single CNV identified within the PPCD1 interval proved not to be present after validation was performed. The most plausible explanation for the identification of a CNV that is not subsequently observed by PCR is a false positive result associated with the phenomenon of competitive hybridization observed with high-density array designs. In this case, the observation of the 318 bp loss only in the affected individuals may be due to the presence of a smaller genetic variation (i.e., SNV or small indel) in these individuals that results in an alteration in the competitive hybridization of the three involved probes.
No non-synonymous coding variants were detected in any of the annotated genes within the linked region, consistent with previous reports that failed to identify non-synonymous coding region variants in multiple genes within the PPCD1 locus. However, the recent association of another corneal dystrophy with a synonymous substitution in COL17A1 that creates a cryptic splice donor site, resulting in the loss of 18 amino acids, highlights the potential pathogenicity of synonymous substitutions [23, 24] . Therefore, we performed an in silico analysis of the synonymous substitutions identified in OVOL2 and CCM2L. The synonymous substitutions in OVOL2 was not predicted to create a cryptic splice site while one bioinformatics tool predicted that the synonymous substitution in CCM2L creates a relatively weak cryptic splice acceptor site in comparison to the wild type splice acceptor site. Thus, the exclusion of potentially pathogenic coding region SNVs and CNVs in the PPCD1 interval indicates that the genetic variant responsible for PPCD1 is likely in a non-coding region. Of particular interest, the novel SNV that we report in the promoter region of OVOL2 (c.-307T>C) results in the formation of a binding site motif for the transcription factor FOXO3, a promoter of gene transcription [25] .
Given the pathogenic role of ZEB1 in PPCD3, and the fact that OVOL proteins are involved in the suppression of ZEB1 transcription, OVOL2 is a functional as well as positional candidate gene for PPCD1 [26] [27] [28] [29] . To this end, the observation that OVOL2 protein was elevated in the corneal endothelium of one of the corneas from two individuals with PPCD provides some evidence to support this hypothesis. Although these corneas were obtained from individuals in whom Sanger sequencing of the exons in the ZEB1 gene did not reveal a pathogenic mutation, it may not necessarily be assumed that both of these individuals have PPCD1 as neither are members of a family linked to the PPCD1 interval. Thus, the failure to detect OVOL2 expression in the corneal endothelium of one individual does not exclude the possibility that OVOL2 may be ectopically expressed in the corneal endothelium in individuals with PPCD1.
Although intronic, ncRNA, and intergenic variants were not analyzed in this study, these variants may have potentially pathogenic effects. In particular, intronic variants may also lead to formation of cryptic splice sites and aberrant alternative splicing. Additional regulatory elements may also exist in the intronic and intergenic regions, which may cause abnormal expression of protein-coding genes. Additionally, studies show that ncRNA such as microRNA and long intergenic non-coding RNA, have potentially important functional roles in regulating gene expression [30] . Since the causative variant or gene has yet to be identified, we advocate identification and screening of non-coding variants of the PPCD1 locus and suggest that variants affecting the expression of OVOL2 may be causative of PPCD1.
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